[{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGM0504","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"BrightGene New Bio-Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGM0504","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ BrightGene New Bio-Medical Technology","highestDevelopmentStatusID":"10","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ BrightGene New Bio-Medical Technology"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"BrightGene New Bio-Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGM0504","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ BrightGene New Bio-Medical Technology","highestDevelopmentStatusID":"10","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ BrightGene New Bio-Medical Technology"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by BrightGene Bio-Medical Technology Co.,Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 15, 2025

                          Lead Product(s) : BGM0504,Inapplicable

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 16, 2025

                          Lead Product(s) : BGM0504,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 09, 2025

                          Lead Product(s) : Paracetamol,Metformin,Warfarin Sodium,BGM0504

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 04, 2025

                          Lead Product(s) : BGM0504,Inapplicable

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : BGM0504,Inapplicable

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : BGM0504,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : BrightGene New Bio-Medical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : BGM0504,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : BrightGene New Bio-Medical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank